NIH Director Francis Collins, MD, PhD, is working to improve funding for research into new treatments for lupus and RA through the Accelerating Medicines Partnership, a coalition of private and public partners identifying and validating promising biological targets for therapeutics…
The Centers for Disease Control and Prevention (CDC) has awarded the American College of Rheumatology’s (ACR) The Lupus Initiative (TLI) with a five-year grant to support the development of a national, grassroots program targeting primary care providers, persons with undiagnosed Lupus and rheumatology health care providers. The program will have three components: Immediate dissemination of…
NEW YORK (Reuters Health)—Psoriasis and psoriatic arthritis are associated with an increased risk of migraine, according to new research from Denmark. “The main finding of our study was a psoriasis severity-dependent increased risk of new-onset migraine, and patients with severe skin psoriasis and psoriatic arthritis appeared to have the highest risk,” Dr. Alexander Egeberg from…
(Reuters Health)—When patients have drug benefits that encourage them to save money by using certain pharmacies, they may end up filling more prescriptions, a company-funded study suggests. Narrow pharmacy networks that cover prescriptions only at certain retailers and drug benefits that offer consumers lower out-of-pocket fees at a subset of preferred pharmacies have become more…
What struck me first as I walked by the exam room where Lynn P. sat was the swelling in her fingers and wrists. The bloated hands rested unnaturally on her thighs, palms up, fingers slightly flexed. Her strawberry-blond curls were offset by a high-neck, loose-fitting, burgundy sweater. Her pale skin matched her trim slacks. She had…
PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…
For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…
Questions around prescribing steroids as bridge therapy, in long-term low dosages, or low-dose timed-release formulas, or not at all evoke controversy among rheumatologists
Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets